Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous abatacept in methotrexate-inadequate responder rheumatoid arthritis
NL-OMON31814Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ACR20 response at Month 6. Started Sep 2008; status: active, not recruiting.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON31814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31814.